MedTrace Logo

A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers

NCT02873767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-02-09

No results posted yet for this study

Summary

This study is designed to evaluate the safety and tolerability of single ascending doses of UCB4019 administered by subcutaneous injection in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

PR1

* Active substance: UCB4019 * Route of Administration: subcutaneously

OTHER

PL1

* Active substance: Placebo * Concentration: 0.9 % saline * Route of Administration: subcutaneously

Sponsors & Collaborators

  • UCB Biopharma S.P.R.L.

    lead INDUSTRY

Principal Investigators

  • UCB Cares · UCB (+1 887 822 9493)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02873767 on ClinicalTrials.gov